
Full INTerpath-001 results show the individualized mRNA therapy plus pembrolizumab reduced recurrence risk in resected stage IIB-IV melanoma.
Supplements and Featured Publications
over 18 years ago
A Health Economic Model of Breakthrough Painover 18 years ago
Introductionover 18 years ago
Participating Faculty





